文献速递肝病

转录组学鉴定凝血酶敏感蛋白-2作为NASH和晚期肝纤维化的生物标志物

Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
PubMed 文献 · Hepatology · 2021-08-21

研究对98例活检证实的NAFLD患者肝组织进行RNA测序,发现THBS2基因编码的TSP-2在NASH和晚期纤维化中上调,肝内THBS2诊断NASH和晚期纤维化的AUROC分别为0.915和0.957。在213例患者血清中验证,血清TSP-2预测NASH和晚期纤维化的AUROC分别为0.776和0.856,与FIB-4、HA和NFS相当,并可分层肝并发症风险。

要点

  • 肝内THBS2表达诊断NASH和晚期纤维化的AUROC分别为0.915和0.957。
  • 血清TSP-2预测NASH和晚期纤维化的AUROC分别为0.776和0.856。
  • 血清TSP-2水平与血小板计数是NASH和晚期纤维化的独立预测因素。

核心结论

  • TSP-2可能作为NAFLD患者NASH和晚期纤维化诊断的有用生物标志物。

研究设计与样本

  • 对98例活检证实的NAFLD患者肝组织进行全局RNA测序。
  • 在213例活检证实的NAFLD患者中测量血清TSP-2表达。

主要发现

  • 无监督层次聚类将NASH与非酒精性单纯脂肪肝(NAFL)明确区分,NASH患者呈现反映病理特征的分子异常。
  • 肝内THBS2表达诊断NASH和晚期纤维化(F3-F4)的AUROC分别为0.915和0.957。
  • THBS2与NAFLD活动度评分中的炎症和气球样变、血清AST和透明质酸(HA)水平及NAFLD纤维化评分(NFS)正相关。
  • 血清TSP-2在NASH中显著高于NAFL,并随纤维化分期增加而升高。
  • 血清TSP-2预测NASH和晚期纤维化的AUROC分别为0.776和0.856,在晚期纤维化诊断中与FIB-4、血清HA和NFS相当。

关键数值与推荐

  • 肝内THBS2诊断NASH的AUROC为0.915,诊断晚期纤维化的AUROC为0.957。
  • 血清TSP-2预测NASH的AUROC为0.776,预测晚期纤维化的AUROC为0.856。
  • 血清TSP-2在晚期纤维化诊断中的AUROC与FIB-4、血清HA和NFS相当。

临床怎么用

  • 血清TSP-2可作为NAFLD患者NASH和晚期纤维化的无创诊断标志物。
  • 血清TSP-2水平可辅助分层NAFLD患者肝脏并发症(肝癌、失代偿性肝硬化事件)风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. APPROACH AND RESULTS: Global RNA sequencing of liver tissue from 98 patients with biopsy-proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished NASH from nonalcoholic fatty liver (NAFL), and patients with NASH exhibited molecular abnormalities reflecting their pathological features. Transcriptomic analysis identified proteins up-regulated in NASH and/or advanced fibrosis (stage F3-F4), including matricellular glycoprotein thrombospondin-2 (TSP-2), encoded by the thrombospondin 2 (THBS2) gene. The intrahepatic THBS2 expression level showed the highest areas under the receiver operating characteristic curves (AUROCs) of 0.915 and 0.957 for diagnosing NASH and advanced fibrosis, respectively. THBS2 positively correlated with inflammation and ballooning according to NAFLD activity score, serum aspartate aminotransferase and hyaluronic acid (HA) levels, and NAFLD Fibrosis Score (NFS). THBS2 was associated with extracellular matrix and collagen biosynthesis, platelet activation, caspase-mediated cleavage of cytoskeletal proteins, and immune cell infiltration. Serum TSP-2 expression was measured in 213 patients with biopsy-proven NAFLD, was significantly higher in NASH than in NAFL, and increased parallel to fibrosis stage. The AUROCs for predicting NASH and advanced fibrosis were 0.776 and 0.856, respectively, which were comparable to Fibrosis-4 index, serum HA level, and NFS in advanced fibrosis diagnosis. Serum TSP-2 level and platelet count were independent predictors of NASH and advanced fibrosis. Serum TSP-2 levels could stratify patients with NAFLD according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events. CONCLUSIONS: TSP-2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kozumi K, Kodama T, Murai H, et al. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. 2021. PMID: 34105780. doi:10.1002/hep.31995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。